A study by Mass Eye and Ear (which was published in JAMA Ophthalmology) found that those on semaglutide were four times more likely to develop NAION (17 of 200 diabetes patients) and seven times more likely to develop NAION if they were also obese or overweight (20 of 361 overweight or obese patients)
Serious but Rare Side Effects More serious side effects occur in less than 1% of patients but require immediate medical attention: Severe allergic reactions Pancreatitis (inflammation of the pancreas) Kidney problems Diabetic retinopathy complications Thyroid tumors (seen in animal studies) Safety Risks with Compounded Versions Compounded semaglutide carries additional safety concerns beyond those associated with the active ingredient itself: Contamination risk: Less stringent manufacturing conditions may increase infection risk Dosing errors: Inconsistent potency could lead to under-dosing or overdosing Unknown additives: Additional ingredients may cause allergic reactions Lack of safety data: No clinical trials specifically test compounded formulations Cost Analysis Ozempic Pricing Brand-name Ozempic typically costs between $800 to $1,000 per month without insurance coverage
Sharp Needles: Prefer cannulas to reduce tissue trauma and the likelihood of puncturing blood vessels
If you see these patterns in any GLP-1 telehealth platform's marketing, they are the exact claims FDA has called misleading: Calling compounded semaglutide or tirzepatide a "generic" version of Ozempic or Wegovy - compounded drugs are not FDA-approved generics Implying FDA approved or reviewed the compounded product for safety, effectiveness, or quality - the FDA hasn't Claiming the pharmacy is "FDA-approved" or "FDA-licensed" - FDA registers facilities but does not "approve" or "license" compounding pharmacies in the way that phrase implies Branding compounded medication with the telehealth company's name in a way that suggests the telehealth company is the compounder - they're not Any messaging that implies the compounded product is "clinically proven" to perform the same as the FDA-approved branded drug This article avoids all of those patterns
A new kind of experimental medication called retatrutide is yielding impressive blood sugar and weight loss results for people with type 2 diabetes, according to the drugmaker, Eli Lilly
